Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.

Abstract: Compositions, methods of manufacture, methods of improving dietary health, kits, devices, and uses for plasma activated water are provided. Plasma activated water may be used for improving nitric oxide levels, improving health and/or reducing symptoms of cardiometabolic syndrome in a subject. Compositions and methods for improving nitric oxide levels in a subject disclosed herein comprise consumption of a composition comprising dietary nitrate contained in plasma activated water. The health benefits of consuming plasma activated water include lowering blood pressure, lowering intraocular pressure, decreasing LDL/TG levels, restoring nitric oxide mediated cardiovascular benefits, including but not limited, restoring endothelium function and improving flow mediated dilation in nitric oxide deficient subjects. In addition, consumption of plasma activated water also improves oral health and reduces and/or prevents cancer burden.

Abstract: The present invention relates to antimicrobial formulations. More particularly, the invention relates to monovalent copper-containing and/or monovalent copper-generating products for healing wounds and burns, and particularly for chronic wounds, prevention of wound infections and infections in various implants as well as medical/surgical devices.

Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.

Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.

Abstract: The present disclosure provides recombinant T cells that include a vector encoding one or more of peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1-alpha (PGC1?), mitochondrial transcription factor A (Tfam), GA binding protein transcription factor alpha subunit (GABPA), and estrogen-related receptor alpha (ERR? ). Such recombinant T cells can also include a chimeric antigen receptor (CAR) or a recombinant T cell receptor (TCR). Methods of using these recombinant T cells in cancer immunotherapy are provided. Also provided are kits and compositions that can be used with such methods.

Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.

Abstract: The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.

Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.

Abstract: Provided are methods for genetically engineering cells, including cells for use in connection with genetic engineering. In some embodiments, the provided methods including transduction of cells by incubation with a retroviral vector particle, e.g. lentiviral vector, in which, prior to the incubation, the cells have not been incubated with an activating or stimulating agent, such as have not been incubated with anti-CD3/anti-CD28 antibodies and/or one or more recombinant cytokines. In some embodiments, such methods result in features related to shortening or improving the process for genetically engineering cells. Also provided are resulting cells, transduced with a recombinant or heterologous gene, such as one encoding a chimeric receptor such as a chimeric antigen receptor, or other recombinant antigen receptor such as a transgenic T cell receptor, and compositions thereof. In some embodiments, the provided cells and compositions can be used in methods of adoptive immunotherapy.

Abstract: An undifferentiated stem cell removal agent is provided, containing at least one component selected from the group consisting of the following (a) to (d): (a) a cell that is capable of specifically inhibiting proliferation of a glypican-3-expressing cell; (b) a compound that is capable of specifically inhibiting proliferation of a glypican-3-expressing cell; (c) a cell that is capable of inducing a specific immune response against a glypican-3-expressing cell; and (d) a compound that is capable of inducing a specific immune response against a glypican-3-expressing cell.

Abstract: Described herein are methods of promoting engraftment of a cell transplant and methods of killing hematopoietic stem cells by administering a population of T cells, NK cells or cytotoxic immune effector cells comprising a cell-surface receptor for a stem cell-specific antigen. Also described herein is a composition comprising T cells, NK cells or cytotoxic immune effector cells genetically modified to encode a cell-surface receptor for a stem cell-specific antigen.

Abstract: Provided herein are compositions and methods related to the treatment of multiple sclerosis in a subject.

Abstract: In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes (“MILs”). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs.

Abstract: The present disclosure provides methods of treating defects such as wrinkles or scars via a subdermal injection of placental tissue components. It also provides placental tissue compositions maintained within the barrel of a syringe, which may be for use in treating such defects.

Abstract: A frozen therapeutic dose includes an amniotic material and is configured into a pack for easy administering of the dose to a treatment location. A frozen therapeutic dose may contain a concentration of live amniotic stem cells. A frozen therapeutic dose may be provided in a form, such as a multi-pack form, to enable a person to administer a dose to a treatment location without the need of traveling to a doctor's office or clinic. A frozen therapeutic dose package may be kept in a conventional freezer at ?20° C., for example, for extended periods of time and a person may remove the package as needed for treatment. A frozen dose package or pack may contain a secondary material configured to mix with the frozen therapeutic dose. A secondary material may be configured within a single dose compartment with the frozen dose or within a separate compartment.

Abstract: The present disclosure relates to methods of treating cerebral palsy and hypoxic-ischemic brain injury. More particularly, the present disclosure relates to methods of using cord blood or components thereof to treat cerebral palsy and hypoxic-ischemic brain injury. The present disclosure also relates to methods of assessing neuroprotective activity of a neuroprotective agent.

Abstract: A method of preparing a stem-cell containing solution for dental implant treatment, comprising: storing a mixture of a blood sample and ethylenediaminetetraacetic acid (EDTA) at a temperature between 2 and 12 degrees Celsius for a time period of from 3 hours to 72 hours so as to have said mixture separates into an upper layer and a lower layer, wherein the upper layer comprises multiple somatic stem cells; collecting said first upper layer; after said collecting said upper layer, centrifuging said upper layer so as to form a first liquid and a pellet containing said somatic stem cells and said platelets; removing substantially all or a portion of the first liquid and leaving the pellet; re-suspending the pellet in a second liquid to form a stem-cell containing solution; and applying the stem-cell containing solution to a porous titanium-oxide layer on an outer thread of a dental implant.

Abstract: Provided herein are methods and compositions related to Veillonella bacteria useful as therapeutic agents.

Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Abstract: A composition for human and animal use as a therapy for the treatment of tumors, acquired immunodeficiency syndrome and leukemias is described. The composition, for human and animal use as an antitumor agent, has a strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 which is able to strongly stimulate the production of pro-inflammatory cytokines (Th1) interferon INF-gamma, the cytokines exhibiting a marked antitumor activity, and/or a strain of bacteria Lactobacillus salivarius LS06 DSM 26037 which is able to strongly stimulate the production of dendritic cells, the dendritic cells also exhibiting a marked antitumor activity.

Abstract: A virus-like particle of Senecavirus A, the particle including a structural protein VP0, a structural protein VP1 and a structural protein VP3. The structural protein VP0 is encoded by a gene sequence represented by SEQ ID NO: 1. The structural protein VP1 is encoded by a gene sequence represented by SEQ ID NO: 2. The structural protein VP3 is encoded by a gene sequence represented by SEQ ID NO: 3.

Abstract: Bacteriophage covalently attached to a carrier particle with an average diameter of from 0.1 microns to 15 microns, are used in topical treatment of bacterial infection. Bacteriophage covalently attached to a carrier particle of average diameter 7 microns or less are used in systemic treatment of bacterial infection. A plurality of bacteriophages lytic against different bacterial strains gives wide antibacterial activity. A combination therapy comprises administration of antibiotic and bacteriophage covalently attached to a carrier particle.

Abstract: A composition includes an oncolytic adenovirus. The composition can be used for treating retinoblastoma or removing or reducing metastases, secondary malignancies and or trilateral retinoblastoma associated with retinoblastoma. The oncolytic adenovirus has a sequence encoding a hyaluronidase enzyme inserted into its genome, and includes replication machinery specific for tumor cells.

Abstract: A recombinant oncolytic virus, a synthetic DNA sequence and applications of the virus. The recombinant oncolytic virus includes a genome and an exogenous DNA sequence inserted in the genome. The exogenous DNA sequence adapts to express a basic peptide fragment, to increase the environmental pH in a host infected by the recombinant oncolytic virus. More than 60% of amino acids in the basic peptide fragment are basic amino acids. The recombinant oncolytic virus and the synthetic DNA sequence of the disclosure are used to prepare an anti-tumor drug.

Abstract: The present invention provides a new method for preventing and controlling viral diseases in salmonid fish using Quillaja extracts, wherein said method comprises administering to salmonid fish an effective amount of a medicinal composition comprising a Quillaja saponaria extract as active ingredient.

Abstract: The present invention relates to a chemical composition characterized in that it comprises:—the molecule A or a physiologically acceptable salt thereof, and/or:—the molecule B or a physiologically acceptable salt thereof, said molecule A having the following formula: and the molecule B having the following formula: the molecule A or a physiologically acceptable salt thereof being biologically active and stimulating immune activity, the molecule B or a physiologically acceptable salt thereof being biologically active and stimulating immune activity.

Abstract: Composition and methods for treating brain “plaques” and “tangles” in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and an oolong tea extract.

Abstract: A method for promoting weight management in a mammal is provided, comprising administering to the mammal a weight loss agent and a mitochondria enhancing agent. Compositions for weight management are also provided.

Abstract: Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodiments, the combination and/or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.

Abstract: A nutraceutical food product includes a solid matrix and a liquid combined into a gel. The nutraceutical food product may include an immune modulator, such as transfer factor and/or a nanofraction immune modulator. A fruit component may be included in the nutraceutical food product. The fruit component may include at least one oligoproanthocyanidin-containing fruit, such as açai.

Abstract: A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-cessation and promotion of healthy ageing in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b). The composition may comprise a third active ingredient in combination with the Cyperus esculentus extract and mangiferin or norathyriol.

Abstract: The present disclosure relates to a herbal compound extract to moderate diabetes with liver necrosis and fibrosis and applications thereof wherein a herbal compound consists of 10 to 20 units rhizome of Dendrobium nobile Lindl, 6 to 12 units fruiting body of Antrodia camphorata, 12 to 20 units root of Panax ginseng C. A. Mey, 10 to 30 units root of Rehmannia glutinosa Libosch, 15 to 30 units rhizome of Salvia miltiorrhiza Bge., 6 to 12 units all of Pheretima asperfillm (E. Perrier), 10 to 30 units root of Pueraria mirifica, 8 to 15 units fruit of Schisandra chinensis (Turcz.) Baill and 6 to 8 units rhizome of Glycyrrhiza uralensis Fisch and the herbal compound extract is able to moderate symptoms comprising hyperglycemia, hyperlipidemia, abnormal liver function about liver necrosis and fibrosis due to the diabetes.

Abstract: A method of treating cancer, parasite, microbial or fungal disease, comprising administering a Ginger (Zingiber officinale) extract solution to treat the cancer, parasite, microbial or fungal disease; wherein the Ginger (Zingiber officinale) extract solution comprises extracts of Ginger (Zingiber officinale), and a DMSO (dimethyl sulphoxide) solvent; and wherein the extracts of Ginger (Zingiber officinale) are obtained by cold pressing; and an effective dose of the extracts of Ginger (Zingiber officinale) is between a range of 25 ?g/ml-12800 ?g/ml, and a content of the DMSO (dimethyl sulphoxide) solvent is between a range of 0.1-2 wt %; and an anti-parasite effective dose of the extracts of Ginger (Zingiber officinale) on Toxoplasma gondii is 50 ?g/ml-3200 ?g/ml, and the content of the DMSO (dimethyl sulphoxide) solvent is 0.1 wt %.

Abstract: Provided herein are methods of treating nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and/or elevated de novo lipogenesis (DNL) by inhibiting caspase-2 activity or expression. Also disclosed are methods of screening for agents useful in such methods.

Abstract: The present invention provides compositions and methods for the treatment of Sjogren's syndrome (SS) and SS-related symptoms in human subjects by synthetic peptides based on the sequence of CDR1 of an anti-DNA monoclonal antibody.

Abstract: The application is directed to a method of inhibiting or reducing growth of clinical isolate bacteria comprising contacting the clinical isolate with a composition comprising glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof.

Abstract: Disclosed are methods for treating a cognitive or neurological diseases and disorders comprising the step of administering rapastinel or a pharmaceutically acceptable salt, ester or metabolite thereof to a patient in need thereof, wherein rapastinel is administered for an administration period of about one to about fourteen days followed by a holiday period of at least about one to sixteen weeks wherein rapastinel is not administered.

Abstract: The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents.

Abstract: A method of screening a compound or a composition for use in modulating opioid withdrawal symptoms in a mammal. The method comprises the steps of: selecting a group of test animals; separating the group into two subgroups; inducing Panx1 activation or expression in both subgroups; dosing a first subgroup with a candidate compound; dosing a second subgroup with a placebo; measuring ATP released in spinal microglia of test animals in the first subgroup and in the spinal microglia of test animals in the second subgroup; quantifying the difference in ATP released in spinal microglia of test animals in the first subgroup and in the spinal microglia of test animals in the second subgroup; if the difference in the ATP released in the first subgroup and the APT released in the second subgroup is greater than 25%, then formulating the candidate compound into a pharmaceutical composition.

Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/or impairment, pain, and traumatic brain injury.

Abstract: A cyclic polypeptide comprising at least six contiguous amino acids from the amino acid sequence SEQ ID NO:1 Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr for the treatment of autosomal recessive pseudohypoaldosteronism type 1 (PHA type1B) or for the restoration of the Na transport capacity of mutated loss-of-function ENaC.

Abstract: The present invention relates to a composition for inhibiting angiogenesis, containing neo-N-methylsansalvamide (NMSSV), which is a cyclic pentadepsipeptide, as an effective ingredient, and specifically, since the NMSSV of the present invention has excellent activity which inhibits cell migration and tube formation associated with angiogenesis, and concentration-dependently inhibits angiogenesis induced by a vascular endothelial growth factor, it is expected that the NMSSV of the present invention may inhibit angiogenesis and be usefully used as a therapeutic agent for various diseases in which angiogenesis is abnormally regulated.

Abstract: Provided are methods of treating autoimmune diseases. The method entails administering to an individual in need of treatment one or more compositions that contain one or more inhibitors of histone deacetylatse (HDAC) and one or more inhibitors of BRD4. The method can include administering an inhibitor of binding of BRD4 to chromatin, an inhibitor of activation of BRD4 by phosphorylation, an inhibitor of signaling pathways leading to induction or increased expression of Type I interferon stimulated genes (ISG), and combinations thereof. The inhibitors may be administered at a sub-therapeutic dose, and may be administered concurrently or sequentially, in any combination.

Abstract: An arginine-rich polypeptide composition includes an arginine-rich polypeptide and a pharmaceutically acceptable carrier. Generally, the arginine-rich polypeptide has at least nine arginine residues that represent at least 10% of the amino acid residues in the polypeptide. The arginine-rich polypeptide may be used in a method of inhibiting a human papilloma virus (HPV) from binding to a cell, a method of inhibiting intracellular processing of human papilloma virus (HPV) by a cell, or a method of treating a subject having, or at risk of having, a human papilloma virus (HPV) infection.

Abstract: Compositions and method of increasing levels of apoA1 and/HDL in a subject in need thereof are provided. The compositions include one or more TLR5 agonists in a pharmaceutically acceptable carrier in an effective amount to increase the level of apoA1 and/or HDL in a subject. In a preferred embodiment, the composition is an oral formulation of the one or more TLR5 agonists. The disclosed methods include administering compositions containing the one or more TLR5 agonists to a subject in need thereof, in an effective amount to increase levels of apoA1 and/or HDL in the subject. In one preferred embodiment, the subject is at risk of developing atherosclerosis and/or coronary heart disease. In some embodiments, the subject is diagnosed as having atherosclerosis. The disclosed compositions can also be administered to subjects presenting with hyperlipidemia or hypercholesterolemia.

Abstract: The present invention relates to an Nkx3.2 fragment with improved stability under a histopathological environment of arthritis and to a pharmaceutical composition containing the same as an active ingredient. The Nkx3.2 fragment of the present invention has a function to activate NF-?B at the similar level to full-length Nkx3.2 and resistance to proteolysis by Siah1. In addition, the Nkx3.2 fragment exhibited at least a 10-fold improvement in degenerative arthritis treatment effect compared with Nkx3.2 in an animal model-based in vivo efficacy evaluation. Therefore, the Nkx3.2 fragment can be favorably used in the prevention or treatment of arthritis.

Abstract: The present invention relates to use of a human C3a receptor agonist in the manufacture of a medicament for the treatment or prevention of an ischemic brain injury, wherein the medicament is formulated for intranasal delivery, human C3a receptor agonist for such use, as well as devices for intranasal administration comprising a human C3a receptor agonist and kits comprising such devices.

Abstract: The invention provides methods and compositions relating to molecular targets associated with treating or preventing hypoglycemia. Included in the invention are methods and compositions relating to inhibiting the expression or activity of a glucose modulating agent associated with hypoglycemia e.g., Fibroblast Growth Factor 19 (FGF19). Also included in the invention are methods and compositions for increasing the blood glucose level of a subject. Additional aspects of the invention relate to methods for determining whether a subject has or is at risk for developing hypoglycemia, for example, post-bariatric hypoglycemia.